157 related articles for article (PubMed ID: 20961187)
1. Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis.
Gugliucci A; Kinugasa E; Kotani K; Caccavello R; Kimura S
Clin Chem Lab Med; 2011 Jan; 49(1):61-7. PubMed ID: 20961187
[TBL] [Abstract][Full Text] [Related]
2. Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Padra J; Paragh GJ; Asztalos L; Paragh G
Nephrol Dial Transplant; 2012 Jul; 27(7):2866-72. PubMed ID: 22247228
[TBL] [Abstract][Full Text] [Related]
3. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
4. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL.
Gugliucci A; Kinugasa E; Ogata H; Caccavello R; Kimura S
Clin Chim Acta; 2014 Mar; 430():9-14. PubMed ID: 24384301
[TBL] [Abstract][Full Text] [Related]
5. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis.
Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW
Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020
[TBL] [Abstract][Full Text] [Related]
6. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients.
Saeed SA; Elsharkawy M; Elsaeed K; Fooda O
Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870
[TBL] [Abstract][Full Text] [Related]
7. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease.
Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ
Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192
[TBL] [Abstract][Full Text] [Related]
9. Increased oxidized-LDL levels and arylesterase activity/HDL ratio in ESRD patients treated with hemodialysis.
Mahrooz A; Zargari M; Sedighi O; Shaygani H; Gohari G
Clin Invest Med; 2012 Jun; 35(3):E144-51. PubMed ID: 22673317
[TBL] [Abstract][Full Text] [Related]
10. Activity of paraoxonase 1 (PON1) on HDL
Miljkovic M; Stefanovic A; Vekic J; Zeljkovic A; Gojkovic T; Simic-Ogrizovic S; Bogavac-Stanojevic N; Cerne D; Ilic J; Stefanovic I; Jelic-Ivanovic Z; Spasojevic-Kalimanovska V; Kotur-Stevuljevic J
Clin Biochem; 2018 Sep; 60():52-58. PubMed ID: 30130521
[TBL] [Abstract][Full Text] [Related]
11. Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis.
Zohny SF; El-Fattah MA; Khan JA
Clin Invest Med; 2016 Oct; 39(5):E173-E181. PubMed ID: 27805900
[TBL] [Abstract][Full Text] [Related]
12. Acrolein inactivates paraoxonase 1: changes in free acrolein levels after hemodialysis correlate with increases in paraoxonase 1 activity in chronic renal failure patients.
Gugliucci A; Lunceford N; Kinugasa E; Ogata H; Schulze J; Kimura S
Clin Chim Acta; 2007 Sep; 384(1-2):105-12. PubMed ID: 17632094
[TBL] [Abstract][Full Text] [Related]
13. Postprandial Paraoxonase 1 Activity Following Consumption of Recommended Amounts of Mixed Meals in Healthy Males.
Kameyama N; Maruyama C; Kotani K; Caccavello R; Gugliucci A; Matsui S; Araki R; Maruyama T
J Atheroscler Thromb; 2016; 23(2):225-32. PubMed ID: 26447089
[TBL] [Abstract][Full Text] [Related]
14. Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes.
Gugliucci A; Caccavello R; Nassar H; Abu Ahmad W; Sinnreich R; Kark JD
Clin Chim Acta; 2015 May; 445():41-7. PubMed ID: 25801214
[TBL] [Abstract][Full Text] [Related]
15. Effect of nutritional status on human paraoxonase-1 activity in patients with chronic kidney disease.
Sztanek F; Seres I; Harangi M; Lőcsey L; Koncsos P; Paragh G
Kidney Blood Press Res; 2012; 36(1):310-9. PubMed ID: 23235285
[TBL] [Abstract][Full Text] [Related]
16. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies.
Rosenblat M; Ward S; Volkova N; Hayek T; Aviram M
Biofactors; 2012; 38(4):292-9. PubMed ID: 22674772
[TBL] [Abstract][Full Text] [Related]
17. Renal cortical thickness and PON1 activity both decrease in chronic renal failure.
Ak G; Ozgönül M; Sözmen EY; Aslan SL; Sözmen B
J Nephrol; 2002; 15(2):144-9. PubMed ID: 12018630
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase activity in healthy, diabetic, and hemodialysis patients.
Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A
Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382
[TBL] [Abstract][Full Text] [Related]
19. Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile.
Alaminos-Castillo MÁ; Ho-Plagaro A; García-Serrano S; Santiago-Fernandez C; Rodríguez-Pacheco F; Garrido-Sanchez L; Rodriguez C; Valdes S; Gonzalo M; Moreno-Ruiz FJ; Rodríguez-Cañete A; Montiel-Casado C; Garcia-Fuentes E
Int J Clin Pract; 2019 Jun; 73(6):e13315. PubMed ID: 30681756
[TBL] [Abstract][Full Text] [Related]
20. Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies.
Efrat M; Rosenblat M; Mahmood S; Vaya J; Aviram M
Atherosclerosis; 2009 Feb; 202(2):461-9. PubMed ID: 18585720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
